Promisnig results from a recent phase 2 trial of a new inhaled drug candidate offers new hope for a breakthrough therapy against most known respiratory infections. The trial conducted through Houston-based biotechnology company Pulmotect, Inc. showed that it may be an effective treatment for COVID-19 and even against new viruses that can cause respiratory illnesses. The drug candidate–PUL-042– developed and tested by researchers at the Texas A&M University Health Science Center and University of Texas MD Anderson Cancer Center, showed improvement in cough and shortness of breath more quickly than those who received a placebo treatment. They also experienced fewer hospitalizations and intensive care admissions.

The study found that the inhaled PUL-042 stimulates the lungs’ innate immune system, protecting against a wide variety of respiratory pathogens. The researchers hope that PUL-042 could be directed against all existing and future variants of the COVID-19 virus, as well as future pandemics.